1. Safety and Efficacy of Amiloride in Reducing the Need for Magnesium Supplementation in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Calcineurin Inhibitors 
Gabriel Bartoo, PharmD, Julianna Merten, PharmD, Robert Wolf, PharmD, Ross Dierkhising, MS, David Dingli, MD, Shahrukh K. Hashmi, MD, MPH, William J. Hogan, MBBCh, Mark R. Litzow, MD, Mrinal S. Patnaik, MBBS 
Biology of Blood and Marrow Transplantation 
Volume 22, Issue 3, Pages S116-S117 (March 2016)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1
Total Magnesium Supplementation: Data points represent mean daily magnesium supplementation (IV + oral) for each patient within the three 5-day periods, with day 0 being the day of amiloride initiation Dosage is expressed as bioavailable elemental magnesium, where oral magnesium supplements were estimated to be 33% bioavailable Days -5 to -1 and day 1 to 5 include available data for all patients (n = 33). Days 6 to 10 include available data for patients receiving amilorido for at least 7 days (n = 29). P -values reflect paired t-test companions of each post-amiloride time period wrth the pre-amiloride time period.
Biology of Blood and Marrow Transplantation  , S116-S117DOI: ( /j.bbmt )
Copyright © Terms and Conditions

3. Figure 2
IV Magnesium Supplementation: Data points represent mean daily IV magnesium supplementation for each patient within the three 5-day periods, with day 0 being I ho day of amiloride initiation. Dosage is expressed as elemental magnesium. Days -5 to -1 and day 1 to 5 include available data for all patients (n = 33) Days 6 to 10 include available data for patients receiving amiloride for al least 7 days (n = 29). P-values reflect paired t-test comparisons of each post-amiloride time period with the pre-amiloride time period (differences relative to the pre-amiloride time period and 95% confidence intervals are shown if statistically significant).
Biology of Blood and Marrow Transplantation  , S116-S117DOI: ( /j.bbmt )
Copyright © Terms and Conditions

4. Figure 3
Serum Magnesium Level: Data points represent mean serum magnesium level for each patient within the three 5-day periods, with day 0 being the day of amiloride initiation. Days -5 to -1 and days 1 to 5 include available data for all patients (n = 33). Days 6 to 10 include available data for patients receiving amiloride for at least 7 days (n = 29). P-values reflect paired t-test comparisons of each post-amiloride time period with the pre-amiloride time period (differences relative to the pre-amiloride time period and 95% confidence intervals are shown if statistically significant).
Biology of Blood and Marrow Transplantation  , S116-S117DOI: ( /j.bbmt )
Copyright © Terms and Conditions